Consolidation Therapy With Lenalidomide (Revlimid) With or Without Rituximab Followed by Maintenance Therapy With Revlimid After Autologous/Syngeneic Transplant for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Trial Profile

Consolidation Therapy With Lenalidomide (Revlimid) With or Without Rituximab Followed by Maintenance Therapy With Revlimid After Autologous/Syngeneic Transplant for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Mar 2009 Actual initiation date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 04 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 06 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top